A5019747461- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Parasitic infections in humans and animals
- Bacterial Infections and Vaccines
- Immunotherapy and Immune Responses
- T-cell and Retrovirus Studies
- Viral gastroenteritis research and epidemiology
- Congenital Anomalies and Fetal Surgery
- Parasitic Infections and Diagnostics
- COVID-19 Clinical Research Studies
- Animal Disease Management and Epidemiology
- Leech Biology and Applications
- Urological Disorders and Treatments
- Virology and Viral Diseases
- Parasites and Host Interactions
- Parasite Biology and Host Interactions
- interferon and immune responses
- Helminth infection and control
- vaccines and immunoinformatics approaches
- Influenza Virus Research Studies
The University of Queensland
2020-2024
The University of Melbourne
2010-2012
The University of Adelaide
2007
Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen design through manufacturability vaccine efficacy of a prefusion-stabilised spike (S) protein, Sclamp, in combination with the licensed adjuvant MF59 'MF59C.1' (Seqirus, Parkville, Australia).A panel recombinant Sclamp proteins were produced Chinese hamster ovary screened vitro select lead candidate. The structure this was...
Recombinant antigens from the oncosphere stage of parasite Taenia solium were expressed in Escherichia coli. The TSOL16, TSOL45-1A and TSOL45-1B recombinant antigens, each consisting fibronectin type III (FnIII) domain S, produced as fusion proteins with glutathione S-transferase (GST) maltose binding protein (MBP). Groups pigs immunized twice GST fusions boosted a third time MBP prior to receiving challenge infection T. eggs. TSOL16 antigen was found be capable inducing high levels immunity...
Abstract The human T-lymphotropic virus type 1 (HTLV-1) infects millions of people globally and is endemic to various resource-limited regions. Infections persist for life are associated with increased susceptibility opportunistic infections severe diseases including adult T cell leukemia/lymphoma HTLV-1-associated myelopathy-tropical spastic paraparesis. No HTLV-1-specific anti-retrovirals have been developed it unclear whether existing treatment immunodeficiency (HIV) efficacy against...
DAO Diseases of Aquatic Organisms Contact the journal Facebook Twitter RSS Mailing List Subscribe to our mailing list via Mailchimp HomeLatest VolumeAbout JournalEditorsSpecials 74:235-242 (2007) - doi:10.3354/dao074235 Effect water temperature on reproductive development Benedenia seriolae (Monogenea: Capsalidae) from Seriola lalandi in Australia Julia A. Lackenby1,3,*, Clinton B. Chambers1,4, Ingo Ernst1,5, Ian D. Whittington1,2 1School Earth and Environmental Sciences, Darling Building...
Abstract Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace with more than 30 candidate now in clinical evaluation. Here we describe the preclinical development of an adjuvanted, prefusion-stabilised Spike (S) protein “Sclamp” subunit vaccine, from rational antigen design through assessing manufacturability vaccine efficacy. In mice, elicits high levels neutralising antibodies epitopes both within outside...
Prior to 2020, the threat of a novel viral pandemic was omnipresent but largely ignored. Just twelve months prior Coronavirus disease (COVID-19) our team received funding from Coalition for Epidemic Preparedness Innovations (CEPI) establish and validate rapid response pipeline subunit vaccine development based on proprietary Molecular Clamp platform. Throughout course 2019 we conducted two mock tests system antigen production against potential, emerging pathogens, Achimota paramyxovirus...
Immunohistochemistry and immunofluorescence with confocal microscopy were used to localize the host-protective antigens of Taenia saginata (TSA9 TSA18) solium (TSOL16, TSOL18 TSOL45). In nonactivated oncospheres, TSA9 TSOL45 found primarily in cytoplasm penetration gland type one (PG1) cell. A similar pattern staining was seen for oncospheres T. that remained within oncospheral membrane. addition, there less intense quadri-nucleate 2 (PG2) TSA18, TSOL16 predominantly PG2 activated had...
We previously demonstrated the safety and immunogenicity of an MF59-adjuvanted COVID-19 vaccine based on SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by molecular clamp using HIV-1 41 sequences. Here, we describe 12-month results adults aged 18-55 years ≥56 years.Phase 1, double-blind, placebo-controlled trial conducted Australia (July 2020-December 2021; ClinicalTrials.govNCT04495933; active, not recruiting). Healthy (Part 1: years; Part 2: years) received two doses...
Abstract The human T-lymphotropic virus type 1 (HTLV-1) infects millions of people globally and is endemic to various resource-limited regions. Infections persist for life are associated with increased susceptibility opportunistic infections severe diseases including adult T cell leukemia/lymphoma (ATLL) HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP). No HTLV-1-specific anti-retrovirals have been developed it unclear whether existing treatment immunodeficiency (HIV)...
Background: We assessed the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a prefusion conformation by novel molecular clamp (Sclamp).Methods: Phase 1, double-blind, placebo-controlled trial conducted Australia (July 2020–ongoing; ClinicalTrials.gov NCT04495933). Healthy adults (18-55 years) received two doses placebo, 5-μg, 15-μg, or 45-μg Sclamp, one dose Sclamp followed 28 days apart (n=120; 24...
Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace. Here we describe rational antigen design through manufacturability vaccine efficacy, of a prefusion-stabilised Spike (S) protein, Sclamp. This strategy uses an orthogonal stabilisation approach compared canonical vaccines, in combination with the licensed adjuvant MF59 (Seqirus). In mice, Sclamp elicits high levels neutralising antibodies, as well broadly...
Background: We previously demonstrated the safety and immunogenicity of an MF59-adjuvanted COVID-19 vaccine based on SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by molecular clamp using HIV-1 41 sequences. Here, we describe 12-month results adults aged 18–55 years ≥56 years.Methods: Phase 1, double-blind, placebo-controlled trial conducted Australia (July 2020–December 2021; ClinicalTrials.gov NCT04495933; active, not recruiting). Healthy (Part 1: years; Part 2:...